Histoplasmosis in an off-trail Hiker receiving ustekinumab: Implications for Preventive and diagnostic strategies for patients receiving anti-IL-12/23 therapy

Ustekinumab, an IL-12/23 inhibitor, is an important agent in treatment of inflammatory bowel disease and psoriasis. Clinical trials have not demonstrated significantly increased infection risk with ustekinumab. We report a case of disseminated histoplasmosis in the setting of ustekinumab and methotr...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Yun-Han, Magleby, Reed, Rao, Rema, Walsh, Thomas J., Singh, Harjot K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8010353/
https://www.ncbi.nlm.nih.gov/pubmed/33816098
http://dx.doi.org/10.1016/j.mmcr.2021.03.004
_version_ 1783673046115024896
author Huang, Yun-Han
Magleby, Reed
Rao, Rema
Walsh, Thomas J.
Singh, Harjot K.
author_facet Huang, Yun-Han
Magleby, Reed
Rao, Rema
Walsh, Thomas J.
Singh, Harjot K.
author_sort Huang, Yun-Han
collection PubMed
description Ustekinumab, an IL-12/23 inhibitor, is an important agent in treatment of inflammatory bowel disease and psoriasis. Clinical trials have not demonstrated significantly increased infection risk with ustekinumab. We report a case of disseminated histoplasmosis in the setting of ustekinumab and methotrexate following a hike in the Catskill Mountains, a region not commonly associated with Histoplasma encapsulatum. To our knowledge, this is the first reported case of newly acquired histoplasmosis complicating treatment with ustekinumab.
format Online
Article
Text
id pubmed-8010353
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-80103532021-04-01 Histoplasmosis in an off-trail Hiker receiving ustekinumab: Implications for Preventive and diagnostic strategies for patients receiving anti-IL-12/23 therapy Huang, Yun-Han Magleby, Reed Rao, Rema Walsh, Thomas J. Singh, Harjot K. Med Mycol Case Rep Case Report Ustekinumab, an IL-12/23 inhibitor, is an important agent in treatment of inflammatory bowel disease and psoriasis. Clinical trials have not demonstrated significantly increased infection risk with ustekinumab. We report a case of disseminated histoplasmosis in the setting of ustekinumab and methotrexate following a hike in the Catskill Mountains, a region not commonly associated with Histoplasma encapsulatum. To our knowledge, this is the first reported case of newly acquired histoplasmosis complicating treatment with ustekinumab. Elsevier 2021-03-13 /pmc/articles/PMC8010353/ /pubmed/33816098 http://dx.doi.org/10.1016/j.mmcr.2021.03.004 Text en © 2021 Published by Elsevier B.V. on behalf of International Society for Human and Animal Mycology. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Case Report
Huang, Yun-Han
Magleby, Reed
Rao, Rema
Walsh, Thomas J.
Singh, Harjot K.
Histoplasmosis in an off-trail Hiker receiving ustekinumab: Implications for Preventive and diagnostic strategies for patients receiving anti-IL-12/23 therapy
title Histoplasmosis in an off-trail Hiker receiving ustekinumab: Implications for Preventive and diagnostic strategies for patients receiving anti-IL-12/23 therapy
title_full Histoplasmosis in an off-trail Hiker receiving ustekinumab: Implications for Preventive and diagnostic strategies for patients receiving anti-IL-12/23 therapy
title_fullStr Histoplasmosis in an off-trail Hiker receiving ustekinumab: Implications for Preventive and diagnostic strategies for patients receiving anti-IL-12/23 therapy
title_full_unstemmed Histoplasmosis in an off-trail Hiker receiving ustekinumab: Implications for Preventive and diagnostic strategies for patients receiving anti-IL-12/23 therapy
title_short Histoplasmosis in an off-trail Hiker receiving ustekinumab: Implications for Preventive and diagnostic strategies for patients receiving anti-IL-12/23 therapy
title_sort histoplasmosis in an off-trail hiker receiving ustekinumab: implications for preventive and diagnostic strategies for patients receiving anti-il-12/23 therapy
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8010353/
https://www.ncbi.nlm.nih.gov/pubmed/33816098
http://dx.doi.org/10.1016/j.mmcr.2021.03.004
work_keys_str_mv AT huangyunhan histoplasmosisinanofftrailhikerreceivingustekinumabimplicationsforpreventiveanddiagnosticstrategiesforpatientsreceivingantiil1223therapy
AT maglebyreed histoplasmosisinanofftrailhikerreceivingustekinumabimplicationsforpreventiveanddiagnosticstrategiesforpatientsreceivingantiil1223therapy
AT raorema histoplasmosisinanofftrailhikerreceivingustekinumabimplicationsforpreventiveanddiagnosticstrategiesforpatientsreceivingantiil1223therapy
AT walshthomasj histoplasmosisinanofftrailhikerreceivingustekinumabimplicationsforpreventiveanddiagnosticstrategiesforpatientsreceivingantiil1223therapy
AT singhharjotk histoplasmosisinanofftrailhikerreceivingustekinumabimplicationsforpreventiveanddiagnosticstrategiesforpatientsreceivingantiil1223therapy

Ejemplares similares